Editorial: Alzheimer Disease—What’s in a Name? https://ja.ma/4fpUgtb
JAMA Neurology
Book and Periodical Publishing
Chicago, Illinois 23,166 followers
A member of the JAMA Network, which includes JAMA, 11 specialty journals, and JAMA Network Open.
About us
JAMA Neurology is published online weekly, every Monday, and in 12 print/online issues a year. The journal receives more than 7.7 million annual article views and downloads. Without any author fees, all research articles are made free access online 12 months after publication on the website. In addition, the online version is freely available or nearly so to institutions in developing countries through the World Health Organization's HINARI program. JAMA Neurology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications. The journal’s acceptance rate is 9%. The median time to first decision is 5 days, and 35 days with review. The Journal Impact Factor is 29, one of the highest ranking among neurology journals. All articles are published online first. S. Andrew Josephson, MD, Professor of Neurology and Chair of the Department of Neurology, University of California, San Francisco, is the editor in chief.
- Website
-
https://jamanetwork.com/journals/jamaneurology
External link for JAMA Neurology
- Industry
- Book and Periodical Publishing
- Company size
- 1,001-5,000 employees
- Headquarters
- Chicago, Illinois
- Founded
- 1919
- Specialties
- Neurology
Updates
-
Most viewed in the last 7 days from JAMA Neurology: First-line disease-modifying therapy discontinuation can lead to recurrence of inflammatory disease activity in approximately 20% of cases, even in patients with long-term stable MS. https://ja.ma/4izDxGn
-
-
International Working Group suggests biomarker positive cognitively normal individuals should not be diagnosed as having Alzheimer disease and instead are at-risk. https://ja.ma/41kfWn8
-
-
Case report describes a patient’s experience after seeking a second opinion regarding a brain tumor. https://ja.ma/49D6MUS
-
-
Performance feedback provided through a dashboard used by local quality improvement teams reduced door-to–groin puncture time for endovascular thrombectomy. https://ja.ma/4g9MN2s
-
-
Most viewed in the last 7 days from JAMA Neurology: First-line disease-modifying therapy discontinuation can lead to recurrence of inflammatory disease activity in approximately 20% of cases, even in patients with long-term stable MS. https://ja.ma/3VDN4CD
-
-
The sensitivity of an real-time quaking-induced conversion analysis of a combination of 2 or more skin sites was superior to that of cerebrospinal fluid in diagnosing prion diseases. https://ja.ma/4iuGic4
-
-
Most viewed in the last 7 days from JAMA Neurology: The NOTCH3-small vessel disease (NOTCH3-SVD) staging system captures the full disease severity spectrum associated with CADASIL-type NOTCH3 variants. https://ja.ma/49sf8OT
-
-
Prehospital management in a mobile stroke unit for patients with acute ischemic stroke potentially eligible for intravenous thrombolysis is associated with reduced global disability at hospital discharge. https://ja.ma/3ZzpwAa
-
-
Repeated Neurological Pupil Index measurements were insufficient to replace invasive monitoring in patients with subarachnoid hemorrhage, traumatic brain injury, and intracerebral hemorrhage. https://ja.ma/4f4NBEp
-